RIAPRE - Non-interventional Registry of Anticoagulation Treatment (BI-006-IT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00317343
Recruitment Status : Withdrawn
First Posted : April 24, 2006
Last Update Posted : May 7, 2012
Information provided by:

March 30, 2006
April 24, 2006
May 7, 2012
March 2006
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00317343 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
RIAPRE - Non-interventional Registry of Anticoagulation Treatment (BI-006-IT)
RIAPRE - A Non-interventional Registry on the Anticoagulation Treatment in High Risk Elective Percutaneous Coronary Interventions
RIAPRE is a non-interventional registry to be settled in Italy with the purpose of collecting data on 600 cases of high risk elective percutaneous coronary intervention (PCI) patients treated with an anticoagulation regime different from unfractionated heparin in monotherapy. About thirty catheterization laboratories will co-operate in this activity. The long term outcome of patients will be taken into consideration. The availability of these data will allow for a better understanding of the therapeutic needs in this area.
Not Provided
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Primary care clinic
Coronary Disease
Drug: Bivalirudin (thrombin specific anticoagulant)
Percutaneous Coronary Intervention
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2008
Not Provided

Inclusion Criteria :

  • Medical condition or disease to be studied: age > 18 years.
  • Patients are candidates for a PCI with a planned anticoagulation regime other than unfractionated heparin in monotherapy. Taking into consideration the national and international guidelines for this area and the registered indications of the drugs currently used for this purpose it is predicted that the patients will probably receive one of the following:

    • unfractionated heparin as an intravenous (IV) bolus followed by IV bolus + infusion of a GPI (abciximab, tirofiban or eptifibatide); or
    • bivalirudin as an IV bolus followed by IV infusion, as per the pertinent Summary of Product Characteristics (SPCs).
  • Having provided an informed consent (to anonymous data treatment).
  • A planned anticoagulation regime means that any candidate patient should be identified on the basis of pre-procedural factors and requested to give his/her consent before the PCI is initiated. Patients receiving bail-out GPI for intraprocedural complications should NOT be considered for the inclusion. However, a pre-included patient could receive a bail-out GPI if deemed necessary.
  • The allocation of any individual patient to the category of "high risk" elective PCI will be made independently and autonomously by the caring physician. However, it is recommended to consider the suitability of patients on the basis of these indicative elements:

    • age > 75 years.
    • known diabetes mellitus (type I or type II).
    • known renal insufficiency, i.e. serum creatinine > 1.8 mg or glomerular filtration rate (GFR) > 60 ml/min (calculated with the Cockroft formula).
    • multivessel or complex procedure.
    • planned stent on a bifurcation.
    • planned stent > 6 cm long.
    • PCI on a degenerated venous bypass: in this particular case a distal protection device should always be used.
    • non ST elevation acute coronary syndrome with a PCI planned later than 72 hours after the diagnosis without clinical instability (= "cooled" non ST elevation acute coronary syndrome). This type of patient is considered to be essentially stable and his/her level of risk can be comparable to the risk of patients who are candidates for elective PCI with additional risk factors as listed above.

Exclusion Criteria:

  • There will be no specific exclusion criteria other than those listed in the Summary of Product Characteristics of every individual agent.
Sexes Eligible for Study: All
18 Years to 90 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Study Chair: Nycomed Clinical Project Management Headquarters
May 2012